David Bond, Md
Clinical trials sponsored by David Bond, Md, explained in plain language.
-
New drug duo aims to tame resistant blood cancers
Disease control OngoingThis study is testing the safety and effectiveness of combining two existing drugs, nivolumab and lenalidomide, for patients with non-Hodgkin or Hodgkin lymphoma that has come back or stopped responding to other treatments. The goal is to see if using these drugs together can bet…
Phase: PHASE1, PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
Immunotherapy joins forces with chemo in fight against Fast-Growing lymphoma
Disease control OngoingThis study is testing whether adding the immunotherapy drug nivolumab to a standard chemotherapy regimen (called DA-REPOCH) works better for treating aggressive B-cell non-Hodgkin's lymphoma. The goal is to see if this combination helps patients live longer without their cancer g…
Phase: PHASE2 • Sponsor: David Bond, MD • Aim: Disease control
Last updated Mar 30, 2026 14:35 UTC